<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmacy News EU &#187; food and drug administration</title>
	<atom:link href="http://www.pharmacynews.eu/tag/food-and-drug-administration/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmacynews.eu</link>
	<description>Latest industry news Pharmacy sector.</description>
	<lastBuildDate>Mon, 06 Sep 2010 20:00:00 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>The Washington Daybook</title>
		<link>http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-28</link>
		<comments>http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-28#comments</comments>
		<pubDate>Mon, 06 Sep 2010 20:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Healthcare News]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[F.R. Page]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[health and human services department hhs]]></category>
		<category><![CDATA[New Hampshire]]></category>
		<category><![CDATA[Silver Spring]]></category>
		<category><![CDATA[silver spring md]]></category>
		<category><![CDATA[waples]]></category>
		<category><![CDATA[Yvette Waples]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-28</guid>
		<description><![CDATA[TIME: 8:30 a.m.EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 47309) holds a meeting of the Psychopharmacologic Drugs Advisory Committee to consider supplemental new drug application (sNDA) 21-897/015, VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence.DATE: September 16, 2010LOCATION: FDA, 10903 New Hampshire Avenue, Building [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-28/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>VMAC Meeting to Consider AquaBounty&#8217;s AquAdvantage Salmon</title>
		<link>http://www.pharmacynews.eu/pharmaceutical-industry/vmac-meeting-to-consider-aquabountys-aquadvantage-salmon-2</link>
		<comments>http://www.pharmacynews.eu/pharmaceutical-industry/vmac-meeting-to-consider-aquabountys-aquadvantage-salmon-2#comments</comments>
		<pubDate>Sun, 05 Sep 2010 19:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Pharmaceutical Industry]]></category>
		<category><![CDATA[AquaBounty]]></category>
		<category><![CDATA[biotechnology company]]></category>
		<category><![CDATA[center for veterinary medicine]]></category>
		<category><![CDATA[Commissioner.              Dr. Ronald Stotish]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[Maryland]]></category>
		<category><![CDATA[quality fish]]></category>
		<category><![CDATA[quot]]></category>
		<category><![CDATA[regulatory responsibility]]></category>
		<category><![CDATA[salmon]]></category>
		<category><![CDATA[U.S. Food]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/pharmaceutical-industry/vmac-meeting-to-consider-aquabountys-aquadvantage-salmon-2</guid>
		<description><![CDATA[AquaBounty Technologies, Inc.(&#34;AquaBounty&#34; or &#34;the Company&#34;) AquaBounty Technologies, Inc. (AIM:ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, announces progress on its pending New Animal Drug Application for AquAdvantage Salmon from the U.S. Food and Drug Administration (&#34;FDA&#34;).The Company confirms that it has been informed by the Center for Veterinary Medicine of [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/pharmaceutical-industry/vmac-meeting-to-consider-aquabountys-aquadvantage-salmon-2/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Can-Fite wins FDA nod for Phase III trial [Globes, Tel Aviv, Israel]</title>
		<link>http://www.pharmacynews.eu/healthcare-news/can-fite-wins-fda-nod-for-phase-iii-trial-globes-tel-aviv-israel</link>
		<comments>http://www.pharmacynews.eu/healthcare-news/can-fite-wins-fda-nod-for-phase-iii-trial-globes-tel-aviv-israel#comments</comments>
		<pubDate>Sat, 04 Sep 2010 19:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Healthcare News]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[dry eye syndrome]]></category>
		<category><![CDATA[e mail services]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Fite]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[Israel]]></category>
		<category><![CDATA[mcclatchy tribune information services]]></category>
		<category><![CDATA[NIS]]></category>
		<category><![CDATA[Tel Aviv]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/healthcare-news/can-fite-wins-fda-nod-for-phase-iii-trial-globes-tel-aviv-israel</guid>
		<description><![CDATA[Sept. 05Can-Fite BioPharma Ltd. (TASE:CFBI) has obtained US Food and Drug Administration (FDA) approval for the Phase III clinical trial of its CF101 anti-inflammatory drug for the treatment of dry-eye syndrome. The trial will last for six months, and include 300 patients in the US, Europe and Israel.Can-Fite added, however, that to register the drug [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/healthcare-news/can-fite-wins-fda-nod-for-phase-iii-trial-globes-tel-aviv-israel/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OREXIGEN THERAPEUTICS, INC. FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Change in Directors or Principal Officers</title>
		<link>http://www.pharmacynews.eu/pharmaceutical-industry/orexigen-therapeutics-inc-files-8-k-disclosing-entry-into-a-material-definitive-agreement-change-in-directors-or-principal-officers</link>
		<comments>http://www.pharmacynews.eu/pharmaceutical-industry/orexigen-therapeutics-inc-files-8-k-disclosing-entry-into-a-material-definitive-agreement-change-in-directors-or-principal-officers#comments</comments>
		<pubDate>Wed, 01 Sep 2010 19:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Pharmaceutical Industry]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[anniversary milestones]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[collaboration agreement]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[contrave]]></category>
		<category><![CDATA[Dante]]></category>
		<category><![CDATA[Dr. Dante]]></category>
		<category><![CDATA[Dr. Lee Dante]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[material definitive agreement]]></category>
		<category><![CDATA[Mexico]]></category>
		<category><![CDATA[U.S. Food]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/pharmaceutical-industry/orexigen-therapeutics-inc-files-8-k-disclosing-entry-into-a-material-definitive-agreement-change-in-directors-or-principal-officers</guid>
		<description><![CDATA[Item 1.01 Entry into a Material Definitive Agreement.Collaboration Agreement with Takeda Pharmaceutical Company LimitedOn September 1, 2010, Orexigen Therapeutics, Inc. (the &#34;Company&#34;) entered into acollaboration agreement (the &#34;Collaboration Agreement&#34;) with TakedaPharmaceutical Company Limited (&#34;Takeda&#34;) to develop and commercializeContrave, the Company&#8217;s investigational drug for the treatment of obesity, inthe United States, Canada and Mexico (the &#34;Territory&#34;). [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/pharmaceutical-industry/orexigen-therapeutics-inc-files-8-k-disclosing-entry-into-a-material-definitive-agreement-change-in-directors-or-principal-officers/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pyng Medical receives clearance from FDA to market FASTx</title>
		<link>http://www.pharmacynews.eu/fda-final-approvals/pyng-medical-receives-clearance-from-fda-to-market-fastx</link>
		<comments>http://www.pharmacynews.eu/fda-final-approvals/pyng-medical-receives-clearance-from-fda-to-market-fastx#comments</comments>
		<pubDate>Wed, 01 Sep 2010 19:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[FDA Final Approvals]]></category>
		<category><![CDATA[adolescent patients]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Datamonitor]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[life applications]]></category>
		<category><![CDATA[Mark]]></category>
		<category><![CDATA[medical device company]]></category>
		<category><![CDATA[Pyng]]></category>
		<category><![CDATA[Robert Silvio]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[us food and drug administration]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/fda-final-approvals/pyng-medical-receives-clearance-from-fda-to-market-fastx</guid>
		<description><![CDATA[Sep 02, 2010 (Datamonitor via COMTEX) Pyng Medical, a Canada-based medical device company, has received 510(k) clearance from the US Food and Drug Administration, or FDA, to market the FASTx sternal intraosseous device.The FASTx sternal intraosseous device is indicated for use in establishing a sternal intraosseous access route in adult and adolescent patients (12 years [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/fda-final-approvals/pyng-medical-receives-clearance-from-fda-to-market-fastx/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New findings from University of Zurich in the area of blood cells described</title>
		<link>http://www.pharmacynews.eu/drug-delivery-systems/new-findings-from-university-of-zurich-in-the-area-of-blood-cells-described</link>
		<comments>http://www.pharmacynews.eu/drug-delivery-systems/new-findings-from-university-of-zurich-in-the-area-of-blood-cells-described#comments</comments>
		<pubDate>Tue, 31 Aug 2010 20:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Delivery Systems]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[phospholipidosis]]></category>
		<category><![CDATA[toxicologic pathology]]></category>
		<category><![CDATA[white blood cells]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/drug-delivery-systems/new-findings-from-university-of-zurich-in-the-area-of-blood-cells-described</guid>
		<description><![CDATA[Fresh data on blood cells are presented in the report &#8216;Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells.&#8217; &#34;Lipid storage disorders and phospholipidosis share similar morphologic characteristics displayed as lamellar bodies at ultrastructural level. More than 50 cationic amphiphilic drugs (CADs), including antidepressants, antianginal, antimalarial, and cholesterol-lowering agents, have [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/drug-delivery-systems/new-findings-from-university-of-zurich-in-the-area-of-blood-cells-described/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BRIEF: Mazor wins FDA nod for combined surgical systems [Globes, Tel Aviv, Israel]</title>
		<link>http://www.pharmacynews.eu/healthcare-news/brief-mazor-wins-fda-nod-for-combined-surgical-systems-globes-tel-aviv-israel</link>
		<comments>http://www.pharmacynews.eu/healthcare-news/brief-mazor-wins-fda-nod-for-combined-surgical-systems-globes-tel-aviv-israel#comments</comments>
		<pubDate>Tue, 31 Aug 2010 19:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Healthcare News]]></category>
		<category><![CDATA[e mail services]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[insight 3d]]></category>
		<category><![CDATA[Mazor]]></category>
		<category><![CDATA[mcclatchy tribune information services]]></category>
		<category><![CDATA[NIS]]></category>
		<category><![CDATA[System]]></category>
		<category><![CDATA[Tel Aviv]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/healthcare-news/brief-mazor-wins-fda-nod-for-combined-surgical-systems-globes-tel-aviv-israel</guid>
		<description><![CDATA[Sept. 01Mazor Surgical Technologies Ltd. (TASE:MZOR) has obtained US Food and Drug Administration (FDA) approval for the company&#8217;s combined spinal surgical system comprising the SpineAssist miniature robotic navigation system and C-Insight 3D imaging system.Mazor believes that the synergy that can be achieved by use of the combined system and the high added value it provides [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/healthcare-news/brief-mazor-wins-fda-nod-for-combined-surgical-systems-globes-tel-aviv-israel/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GlaxoSmithKline receives new FDA PDUFA goal date for ezogabine</title>
		<link>http://www.pharmacynews.eu/drug-delivery-systems/glaxosmithkline-receives-new-fda-pdufa-goal-date-for-ezogabine</link>
		<comments>http://www.pharmacynews.eu/drug-delivery-systems/glaxosmithkline-receives-new-fda-pdufa-goal-date-for-ezogabine#comments</comments>
		<pubDate>Mon, 30 Aug 2010 20:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Delivery Systems]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[mitigation strategy]]></category>
		<category><![CDATA[partial onset seizures]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[us food and drug administration]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/drug-delivery-systems/glaxosmithkline-receives-new-fda-pdufa-goal-date-for-ezogabine</guid>
		<description><![CDATA[Healthcare company GlaxoSmithKline (NYSE:GSK) and pharmaceutical company Valeant Pharmaceuticals International (NYSE:VRX) stated jointly on Monday that the US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for ezogabine to 30 November 2010.The companies added the FDA had set the original goal date of 30 August 2010.Ezogabine is [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/drug-delivery-systems/glaxosmithkline-receives-new-fda-pdufa-goal-date-for-ezogabine/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>21 Drugs Facing FDA Approval Decisions</title>
		<link>http://www.pharmacynews.eu/pharmaceutical-industry/21-drugs-facing-fda-approval-decisions</link>
		<comments>http://www.pharmacynews.eu/pharmaceutical-industry/21-drugs-facing-fda-approval-decisions#comments</comments>
		<pubDate>Mon, 30 Aug 2010 19:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Pharmaceutical Industry]]></category>
		<category><![CDATA[approval decisions]]></category>
		<category><![CDATA[Boston]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[regulatory calendar]]></category>
		<category><![CDATA[svnt]]></category>
		<category><![CDATA[thestreet com]]></category>
		<category><![CDATA[U.S.]]></category>
		<category><![CDATA[U.S. Food]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/pharmaceutical-industry/21-drugs-facing-fda-approval-decisions</guid>
		<description><![CDATA[BOSTON (TheStreet)  The fall will be a very busy time for U.S. drug approvals.For this latest update to my regulatory calendar, I count 21 drugs (impacting 27 different drug and biotech companies) with approval applications to be decided before year&#8217;s end by the regulators at the U.S. Food and Drug Administration.In October alone, the [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/pharmaceutical-industry/21-drugs-facing-fda-approval-decisions/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Washington Daybook</title>
		<link>http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-27</link>
		<comments>http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-27#comments</comments>
		<pubDate>Sun, 29 Aug 2010 20:00:00 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Healthcare News]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[F.R. Page]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[health and human services department hhs]]></category>
		<category><![CDATA[New Hampshire]]></category>
		<category><![CDATA[Silver Spring]]></category>
		<category><![CDATA[silver spring md]]></category>
		<category><![CDATA[waples]]></category>
		<category><![CDATA[Yvette Waples]]></category>

		<guid isPermaLink="false">http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-27</guid>
		<description><![CDATA[TIME: 8:30 a.m.EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 47309) holds a meeting of the Psychopharmacologic Drugs Advisory Committee to consider supplemental new drug application (sNDA) 21-897/015, VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence.DATE: September 16, 2010LOCATION: FDA, 10903 New Hampshire Avenue, Building [...]]]></description>
		<wfw:commentRss>http://www.pharmacynews.eu/healthcare-news/the-washington-daybook-27/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
